This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Reasons to Retain ResMed Stock in Your Portfolio for Now
by Zacks Equity Research
Strong demand for RMD's market-leading mask portfolio raises investors' optimism.
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
by Zacks Equity Research
Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
MASI Stock Down Despite New SafetyNet Deal for Neonatal Care
by Zacks Equity Research
The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
by Zacks Equity Research
TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
HSIC Stock Likely to Get a Boost From New Henry Schein One Launches
by Zacks Equity Research
Henry Schein's dental software arm unveils Dentrix Eligibility offerings to elevate the insurance verification process.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
VEEV Stock Up Following the Release of New Features of Veeva Site Connect
by Zacks Equity Research
Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.
CRL Stock May Benefit From New Neuroscience Research Collaboration
by Zacks Equity Research
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?
by Zacks Equity Research
FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Align Technology Stock Dips on Macroeconomic Issues, FX Headwind
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.
COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD
by Zacks Equity Research
Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
by Zacks Equity Research
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
by Zacks Equity Research
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
Reasons to Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's strong product portfolio raises optimism about the stock.
Boston Scientific (BSX) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $81.37, marking a -0.72% move from the previous day.
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
by Zacks Equity Research
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
Should You Continue to Retain ABT Stock in Your Portfolio Now?
by Zacks Equity Research
Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
Butterfly Network's Stock Surges on iQ3 Device Launch in Europe
by Zacks Equity Research
Shares of BFLY gain almost 27% following the announcement of the launch of its latest handheld ultrasound device, Butterfly iQ3, in Europe.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
by Zacks Equity Research
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
Reasons to Retain STERIS Stock in Your Portfolio for Now
by Zacks Equity Research
STE's strong prospects in the healthcare business arm bode well for investors.
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
by Zacks Equity Research
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
by Zacks Equity Research
EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.